Corruption risk in the Chinese Pharmaceutical market
In 2009, China unveiled a major health care reform initiative which has the objective of providing improved health services to China’s billion-plus population. A still-increasing population and income growth mean that health care spending in China will grow dramatically by 2020, according to some estimates. The potential political fallout if the initiative is seen to be ineffective, and the significant sums of money involved, means that addressing graft in the health care industry is a key component of China’s nationwide anti-corruption drive.
The Point of View (POV), Corruption risk in the Chinese Pharmaceutical market, illustrates the issues and challenges you may face as this situation unfolds, and the importance of having a strategy to address potential problems.